Coloplast A/S revised earnings guidance for the fiscal year 2023/24. For the year, the company the organic revenue growth is still expected to be around 8%. Reported revenue growth in DKK is now expected to be 10-11%, from previously around 11%, and includes negative impact of 1-2%-points from currencies, from previously around 1%-point.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
859.2 DKK | +1.78% | +1.08% | +11.30% |
May. 15 | COLOPLAST : Multiple silver linings in spite of a soft Q2 24 | |
May. 07 | European shares hit one-month high as earnings take centre stage | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.30% | 27.61B | |
-32.85% | 3B | |
+22.22% | 2.45B | |
-20.40% | 2.4B | |
+4.37% | 2.16B | |
+22.22% | 1.92B | |
-10.05% | 1.88B | |
+23.23% | 1.28B | |
+21.08% | 1.27B | |
-4.56% | 1.25B |
- Stock Market
- Equities
- COLO B Stock
- News Coloplast A/S
- Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24